Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection

Anaerobe

Volumn 33, Issue , 2015, Pages 105-108

  Richardson, Connor ^a   Kim, Peter ^a,b   Lee, Christine ^c   Bersenas, Alexa ^a   Weese, J Scott ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Antimicrobial resistance; Clostridium difficile; Fecal microbiota transplantation; Molecular epidemiology

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CDTA GENE; CDTB GENE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; EPSILOMETER TEST; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENT INFECTION; RIBOTYPING; TCDA GENE; TCDB GENE; CLASSIFICATION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; RIBOTYPING; YOUNG ADULT;

EID: 84924580984     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2015.03.003     Document Type: Article

References (31)

1. Pépin J., Valiquette L., Alary M.-E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
2. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 2002, 34:346-353.
3. Pepin J., Alary M.-E., Valiquette L., Raiche E., Ruel J., Fulop K., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 2005, 40:1591-1597.
4. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. Alarge outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 2005, 26:273-280.
5. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N.Engl. J. Med. 2005, 353:2433-2441.
6. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
7. Laffan A.M., Bellantoni M.F., Greenough W.B., Zenilman J.M. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J.Am. Geriatr. Soc. 2006, 54:1068-1073.
8. Marsh J.W., Arora R., Schlackman J.L., Shutt K.A., Curry S.R., Harrison L.H. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J.Clin. Microbiol. 2012, 50:4078-4082.
9. Rodríguez-Pardo D., Almirante B., Bartolomé R.M., Pomar V., Mirelis B., Navarro F., et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona. Spain. J. Clin. Microbiol. 2013, 51:1465-1473.
10. Moore P., Kyne L., Martin A., Solomon K. Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J.Med. Microbiol. 2013, 62:1405-1413.
11. Stewart D.B., Berg A., Hegarty J. Predicting recurrence of C.difficile colitis using bacterial virulence factors: binary toxin is the key. J.Gastrointest. Surg. 2013, 17:118-124.
12. Bidet P., Barbut F., Lalande V., Burghoffer B., Petit J.C. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol. Lett. 1999, 175:261-266.
13. Persson S., Torpdahl M., Olsen K.E.P. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin. Microbiol. Infect. 2008, 14:1057-1064.
14. European Committee on Antimicrobial Suceptibility Testing Breakpoint Tablesfor Interpretation of MICs and Zone Diameters. Version 3.0 2013, http://www.eucast.org.
15. Martin H., Willey B., Low D.E., Staempfli H.R., McGeer A., Boerlin P., et al. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J.Clin. Microbiol. 2008, 46:2999-3004.
16. Jayaratne P.A., Monkman L., Broukhanski G., Pillai D.R., Lee C. Real-time polymerase chain reaction method for detection of toxigenic Clostridium difficile from stools and presumptive identification of NAP1 clone. Diagnostic Microbiol. Infect. Dis. 2013, 75:121-123.
17. Merrigan M., Venugopal A., Mallozzi M., Roxas B., Viswanathan V.K., Johnson S., et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J.Bacteriol. 2010, 192:4904-4911.
18. Pépin J., Valiquette L., Gagnon S., Routhier S., Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 2007, 102:2781-2788.
19. Boone J.H., Goodykoontz M., Rhodes S.J., Price K., Smith J., Gearhart K.N., et al. Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31:1551-1559.
20. Karlstrom O., Fryklund B., Tullus K., Burman L.G. Aprospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile study group. Clin. Infect. Dis. 1998, 26:141-145.
21. Jarvis W.R., Schlosser J., Jarvis A.A., Chinn R.Y. National point prevalence of Clostridium difficile in US health care facility inpatients. Am. J. Infect. Control 2008, 2009(37):263-270.
22. Brandt L.J., Aroniadis O.C., Mellow M., Kanatzar A., Kelly C., Park T., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 2012, 107:1079-1087.
23. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (Fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011, 53:994-1002.
24. Aspevall O., Lundberg A., Burman L.G., Akerlund T., Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob. Agents Chemother. 2006, 50:1890-1892.
25. Drummond L.J., McCoubrey J., Smith D.G., Starr J.M., Poxton I.R. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J.Med. Microbiol. 2003, 52:259-263.
26. Lynch T., Chong P., Zhang J., Hizon R., Du T., Graham M.R., et al. Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One 2013, 8. e53757.
27. Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J.M., Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 2002, 46:1647-1650.
28. Johnson S., Sanchez J.L., Gerding D.N. Metronidazole resistance in Clostridium difficile. Clin. Infect. Dis. 2000, 31:625-626.
29. Moura I., Spigaglia P., Barbanti F., Mastrantonio P. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J.Antimicrob. Chemother. 2013, 68:362-365.
30. Huang H., Weintraub A., Fang H., Wu S., Zhang Y., Nord C.E. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 2010, 16:633-635.
31. Lachowicz D., Pituch H., Obuch-Woszczatyński P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 2015, 31:37-41.